Serum Cytokine Changes in a Patient with Chronic Pulmonary Aspergillosis Overlapping with Allergic Bronchopulmonary Aspergillosis

Intern Med. 2024 Jun 1;63(11):1659-1664. doi: 10.2169/internalmedicine.2234-23. Epub 2023 Oct 27.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA) are diseases caused by Aspergillus infection, and CPA can develop from ABPA in some cases. We herein report a patient with CPA overlapping with ABPA. Serum cytokine levels were evaluated at 4 time points: the ABPA diagnosis, CPA diagnosis, 6 months after the start of voriconazole (VRCZ), and 12 months after re-administration of VRCZ. Interleukin (IL)-13 levels decreased upon glucocorticoid treatment, whereas IL-25 and IL-33 levels decreased rapidly with the initiation of antifungals. Early antifungal therapy may be important to control disease progression and prevent CPA overlap.

Keywords: IL-10; IL-33; allergic bronchopulmonary aspergillosis (ABPA); chronic pulmonary aspergillosis (CPA).

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary* / blood
  • Aspergillosis, Allergic Bronchopulmonary* / complications
  • Aspergillosis, Allergic Bronchopulmonary* / diagnosis
  • Aspergillosis, Allergic Bronchopulmonary* / drug therapy
  • Chronic Disease
  • Cytokines* / blood
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Aspergillosis* / blood
  • Pulmonary Aspergillosis* / complications
  • Pulmonary Aspergillosis* / diagnosis
  • Pulmonary Aspergillosis* / drug therapy
  • Voriconazole* / therapeutic use

Substances

  • Cytokines
  • Voriconazole
  • Antifungal Agents